Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Pre- and posttreatment contrast-enhanced MRI of toxoplasmosis lesion in case 1(A, B) Contrast-enhanced MRI demonstrated a 2.3 by 1.3 cm ring-enhancing.

Published byPhyllis Booker Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Pre- and posttreatment contrast-enhanced MRI of toxoplasmosis lesion in case 1(A, B) Contrast-enhanced MRI demonstrated a 2.3 by 1.3 cm ring-enhancing."— Presentation transcript:

1 Figure 1 Pre- and posttreatment contrast-enhanced MRI of toxoplasmosis lesion in case 1(A, B) Contrast-enhanced MRI demonstrated a 2.3 by 1.3 cm ring-enhancing lesion in the deep white matter of the left frontoparietal lobe. Pre- and posttreatment contrast-enhanced MRI of toxoplasmosis lesion in case 1(A, B) Contrast-enhanced MRI demonstrated a 2.3 by 1.3 cm ring-enhancing lesion in the deep white matter of the left frontoparietal lobe. (C, D) Repeat imaging 1 month later after receiving antitoxoplasmosis treatment. A and C are MRI brain fluid-attenuated inversion recovery sequences. B and D are MRI brain T1 postgadolinium images. Danilo R. Bernardo, Jr, and Nizar Chahin Neurol Neuroimmunol Neuroinflamm 2015;2:e63 © 2015 American Academy of Neurology

Download ppt "Figure 1 Pre- and posttreatment contrast-enhanced MRI of toxoplasmosis lesion in case 1(A, B) Contrast-enhanced MRI demonstrated a 2.3 by 1.3 cm ring-enhancing."

Similar presentations

Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.

Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.
Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.

Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.
Figure 4 Paradoxical immune reconstitution inflammatory syndrome

Figure 4 Paradoxical immune reconstitution inflammatory syndrome
Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.

Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.

Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure 4. Brain imaging and neuropathologic demonstration of Epstein-Barr virus (EBV) encephalitis in patient PT-10 Brain imaging and neuropathologic demonstration.

Figure 4. Brain imaging and neuropathologic demonstration of Epstein-Barr virus (EBV) encephalitis in patient PT-10 Brain imaging and neuropathologic demonstration.
Figure MRI of anti-MOG-IgG–associated myelitis

Figure MRI of anti-MOG-IgG–associated myelitis
Figure 2 Evolution of MRI abnormalities in faciobrachial dystonic seizures Axial fluid- attenuated inversion recovery (FLAIR)-weighted images from patient.

Figure 2 Evolution of MRI abnormalities in faciobrachial dystonic seizures Axial fluid- attenuated inversion recovery (FLAIR)-weighted images from patient.
Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.

Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Fluid-attenuated inversion recovery magnetic resonance imaging at the onset of the clinical investigation (A, B) and 2 months later (C, D). Fluid-attenuated.

Fluid-attenuated inversion recovery magnetic resonance imaging at the onset of the clinical investigation (A, B) and 2 months later (C, D). Fluid-attenuated.
Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Similar presentations

Ads by Google